Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • meazy
    Junior Member
    • Sep 2009
    • 1

    #1

    Exeter exome targeting experiences

    Hi All,

    This is my first post, although, I have been reading all your posts for a while. So thanks!

    We have been playing with some whole exome capture experiments here in Exeter using SureSelect. We get good on target figures, on par with those in the literature.

    We have come across some issues that I’m sure you are all aware of, but I wasn’t so I thought I’d post. Hope it is of interest.

    Whole exome only really means around 75% of the RefSeq genes in build HG18. Nimblegen say 75%, we couldn’t get a figure from Agilent but a quick and dirty gene name count came out with 82%.

    Also start and end co-ordinates in the .bed file for Agilent do not always cover the whole coding region of an exon. They do mostly, but I have found examples of when using the .bed file to return the targeted sequence, only half an exon is covered.
  • ECO
    --Site Admin--
    • Oct 2007
    • 1360

    #2
    I suggest posting your question in the appropriate application area...this forum is just for Introductions.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
      by SEQadmin2



      Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

      Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
      ...
      10-14-2026, 09:55 AM
    • SEQadmin2
      New Genomics Technologies Take Aim at Long-Standing Limits
      by SEQadmin2


      Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

      We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
      ...
      09-28-2026, 10:25 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 10-22-2026, 11:13 AM
    0 responses
    27 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-22-2026, 10:48 AM
    0 responses
    20 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-15-2026, 10:52 AM
    0 responses
    36 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-14-2026, 05:39 AM
    0 responses
    43 views
    0 reactions
    Last Post SEQadmin2  
    Working...